Jonathan Webster

Assistant Professor of Oncology, Division of Hematologic Malignancies, Leukemia Group, Johns Hopkins University

[Johns Hopkins Hematology and Oncology Fellowship @Hopkins_HemOnc]

Congratulations to our fellows (@SaumyaMaruMDPhD, Neha Verma, @mnakazawa7, Nazila Shafagati, Daniel Shu, @michaelconroy, Jesse Handler) on their @ConquerCancerFd #ASCOYIA awards and former fellow and current @hopkinskimmel Asst. Prof. Eric Christenson for the #ASCOCDA!

[Kristina Montemayor @KMonty_MD]

Congratulations @ANiranjanAzadi #OslerPride

[Javier Bolaños Meade, MD @GvHD_Meade]

An incredible amount of work with really brilliant people made #BMTCTN1703 a success and the new SOC for #GvHD prophylaxis #PTCyRules #BMTCTN @CIBMTR Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis | NEJM https://t.co/qXN7YxG5g4

[Johns Hopkins Hematology and Oncology Fellowship @Hopkins_HemOnc]

Congratulations to the graduating class of 2023! We are so proud of you, we love you, and we will miss you. You are all going to do great things!

[Jonathan Webster @LeukDocWebster]

Sending @cappelliMD off to Milan for #EULAR2023 #aleagueoftheirown

[Jonathan Webster @LeukDocWebster]

Great article from @NicholasShortMD and colleagues with important implications for MRD monitoring in Ph+ ALL and our understanding of the fundamental biology underlying Ph+ ALL vs de novo lymphoid blast crisis of CML vs ?Ph+ ALL with CML-like biology.

[Nicholas Short MD @NicholasShortMD]

👉👉Our new paper in @AjHematology on #MRD in Ph+ #ALL. High rates of discordance between NGS for IG/TR and PCR for BCR::ABL1. High sensitivity NGS MRD may be superior to PCR and identifies PCR+ pts with low risk of relapse. Important implications for MRD monitoring in Ph+ ALL.

[Keith W Pratz MD @PratzKW]

#ASH2022 Late breaking abstract on frontline Blinatumomab in adult ALL E1910. Amazing results and new SOC. Congratulations Mark Litzow and study team.

[Keith W Pratz MD @PratzKW]

⁦@DrChrisHourigan⁩ presenting words of wisdom from our great mentor Judy Karp at the #ASH22 AML education session.

[Rakhi Naik, MD MHS @redcell_doc]

Embargo lifted! Congratulations to our @HopkinsHeme trainees who were awarded ASH Abstract Achievement Awards!!
🌟Michael Hochman @mjhochman, Chief Heme Fellow @Hopkins_HemOnc
🌟Macy Early @macy_early, ASH Med Student PS Awardee
🌟 Jayla Scott, Hopkins Woodrow Wilson Awardee 🧵

[Johns Hopkins Thoracic Oncology @HopkinsThoracic]

Congratulations to Dr. @kamarroneMD on receipt of a multi-year career development award from @LUNGevity to study neoadjuvant immunotherapy and targeted therapy for surgical lung cancer harboring a #kras mutation! https://t.co/GBrtqPqI6j

[Jonathan Webster @LeukDocWebster]

Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease | Leukemia https://t.co/nOTDc35WmK

[Keith W Pratz MD @PratzKW]

We are happy to share @DrAndyMatthews work on: Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Thx @SelinaLugerMD @ParalkarLab and UPenn leukemia team https://t.co/VpIBgoKDKh

[Chris Hourigan @DrChrisHourigan]

Live action footage of https://t.co/Ao8A96N3Bf arrival at #ASCO2022 Huge AML MRD dataset to present on Tuesday - but also the hoping to use this time away to write the paper...

[Dr. Catherine Lai @KatieLaiMD_MPH]

Working on a podcast to highlight women pioneers in leukemia. Who do you want to hear from? Also, please re-tweet 👍

[Jonathan Webster @LeukDocWebster]

Clonal Hematopoiesis in Donor May Improve Bone Marrow Transplant Outcome. Great work from ⁦@LukaszPGondek⁩ https://t.co/wmxUDtvrWB

[Jonathan Webster @LeukDocWebster]

Like my decision to join Twitter, this article has been many years in the making. @Dr_BDSmith
https://t.co/0a1ND2V2Vr